SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
******* UPDATE on NeoStem (NBS) *******
An SI Board Since October 2012
Posts SubjectMarks Bans Symbol
0 0 0 NBS
Emcee:  Geney Type:  Moderated
Introduction Market Data Compact
BUY rating and $2.00 PRICE TARGET

Investment analysts at Chardan Capital began coverage on shares of Neostem (NYSE: NBS) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $2.00 price target on the stock.

Shares of Neostem opened at 0.73 on Tuesday. Neostem has a 52 week low of $0.30 and a 52 week high of $0.90. The company’s market cap is $111.4 million.

dailypolitical.com
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News